Announcements Trials
Browse Landscape

Phase

Phase 2 9Phase 3 3Phase 4 2Phase 1/2 2Phase 1 1

Status

Terminated 1Recruiting 1Completed 1

Sponsor Class

OTHER 3INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Carcinoma, Non-Small-Cell Lung 437Breast Neoplasms 382Neoplasms 290Prostatic Neoplasms 192Neoplasm Metastasis 154Multiple Myeloma 147Colorectal Neoplasms 123Lung Neoplasms 104Ovarian Neoplasms 102Parkinson Disease 4, Autosomal Dominant Lewy Body 98Melanoma 95Lymphoma, Follicular 94Recurrence 88Lymphoma, Non-Hodgkin 82Papillomavirus Infections 81Leukemia, Lymphocytic, Chronic, B-Cell 81Carcinoma, Hepatocellular 80Stomach Neoplasms 76Small Cell Lung Carcinoma 72Leukemia, Myeloid, Acute 70Pancreatic Neoplasms 66Pain 66Uterine Cervical Neoplasms 64Carcinoma, Renal Cell 64Keratosis, Actinic 63Urinary Bladder Neoplasms 59Lymphoma, Large B-Cell, Diffuse 53Myasthenia Gravis 52Leiomyoma 49Carcinoma 49

Interventions

enzalutamide 2fludrocortisone acetate 1cabazitaxel 1Prednisone 1Hydrocortisone 1Dexamethasone 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × INDUSTRY × Prostate Cancer Metastatic × Clear all
NCT06136624 2026-05-05

OMAHA-003

Merck Sharp & Dohme LLC

Phase 3 Recruiting
1,310 enrolled
Genitourinary

Prostate Cancer Metastatic

NCT03850795 2024-08-19

HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Hinova Pharmaceuticals USA, Inc.

Phase 3 Terminated
104 enrolled
Genitourinary

Prostate Cancer Metastatic

NCT01254279 2015-01-21

Early Access to Cabazitaxel in Patients With Metastatic Hormone Refractory Prostate Cancer Previously Treated With a Docetaxel-containing Regimen

Sanofi

Phase 3 Completed
984 enrolled
Genitourinary

Prostate Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡